IL121036A0 - Method of enhancing cognition - Google Patents

Method of enhancing cognition

Info

Publication number
IL121036A0
IL121036A0 IL12103697A IL12103697A IL121036A0 IL 121036 A0 IL121036 A0 IL 121036A0 IL 12103697 A IL12103697 A IL 12103697A IL 12103697 A IL12103697 A IL 12103697A IL 121036 A0 IL121036 A0 IL 121036A0
Authority
IL
Israel
Prior art keywords
enhancing cognition
darifenacin
treatment
pharmaceutically acceptable
cognitive impairment
Prior art date
Application number
IL12103697A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL121036A0 publication Critical patent/IL121036A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/01Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01007Acetylcholinesterase (3.1.1.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Control Of Eletrric Generators (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Soil Working Implements (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL12103697A 1996-06-18 1997-06-09 Method of enhancing cognition IL121036A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9612710.5A GB9612710D0 (en) 1996-06-18 1996-06-18 Method of treatment

Publications (1)

Publication Number Publication Date
IL121036A0 true IL121036A0 (en) 1997-11-20

Family

ID=10795468

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12103697A IL121036A0 (en) 1996-06-18 1997-06-09 Method of enhancing cognition

Country Status (15)

Country Link
US (1) US5837724A (pt)
EP (1) EP0813870B1 (pt)
JP (1) JP3453493B2 (pt)
KR (1) KR980000445A (pt)
AT (1) ATE243514T1 (pt)
AU (1) AU2495697A (pt)
CA (1) CA2208111C (pt)
DE (1) DE69722999T2 (pt)
DK (1) DK0813870T3 (pt)
ES (1) ES2197972T3 (pt)
GB (1) GB9612710D0 (pt)
HU (1) HUP9701060A3 (pt)
IL (1) IL121036A0 (pt)
PT (1) PT813870E (pt)
ZA (1) ZA975311B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US7317102B2 (en) * 2003-04-01 2008-01-08 Theravance, Inc. Diarylmethyl and related compounds
AU2009229372C1 (en) 2008-03-27 2017-02-02 Chase Pharmaceuticals Corporation Use and composition for treating dementia
EP3646870A1 (en) * 2009-07-22 2020-05-06 Puretech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
SG10202113198TA (en) * 2017-06-01 2021-12-30 Eisai R&D Man Co Ltd Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
KR102408292B1 (ko) 2018-09-28 2022-06-10 카루나 세러퓨틱스 인코포레이티드 무스카린성 수용체 활성화에 의해 개선된 장애의 치료를 위한 조성물 및 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness

Also Published As

Publication number Publication date
ZA975311B (en) 1998-12-17
ES2197972T3 (es) 2004-01-16
JP3453493B2 (ja) 2003-10-06
DE69722999T2 (de) 2003-12-18
HUP9701060A3 (en) 1999-03-29
PT813870E (pt) 2003-10-31
AU2495697A (en) 1998-01-08
US5837724A (en) 1998-11-17
DE69722999D1 (de) 2003-07-31
DK0813870T3 (da) 2003-08-18
CA2208111A1 (en) 1997-12-18
ATE243514T1 (de) 2003-07-15
HU9701060D0 (en) 1997-08-28
EP0813870B1 (en) 2003-06-25
EP0813870A1 (en) 1997-12-29
JPH1059848A (ja) 1998-03-03
HUP9701060A2 (hu) 1998-12-28
GB9612710D0 (en) 1996-08-21
CA2208111C (en) 2002-10-15
KR980000445A (ko) 1998-03-30

Similar Documents

Publication Publication Date Title
EP0711902A3 (en) Fracturing treatment with nitrogen and carbon dioxide in combination
GB9714544D0 (en) Treated titanium dioxide
HK1046274A1 (en) Spiro Ä1-azabicycloÄ2.2.2.Üoctane-3,2'(3'h)-furoÄ2,3-bÜpyridine for use in the treatment of psychotic and intellectual impairment disorders.
PT936908E (pt) Derivados anticonvulsivos uteis no tratamento de esclerose lateral amiotrofica (ela)
HK1022270A1 (en) Use of anti-microtubule agents for treating or preventing multiple-sclerosis
BG102999A (en) New 2,3-diasubstituted-4-(3h)-quinazolinons
ZA9811507B (en) Combination effective for the treatment of impotence.
PH31324A (en) Method of inhibiting imperfect tissue repair.
EP0672699A3 (en) Copolymers of 1,4-dioxepan-2-one and 1,5,8,12-tetraoxacyclotetracan-7-14-diode.
IL128379A0 (en) Treatment of the common cold or allergic rhinitis
AU7227394A (en) Method for surface treatment, means for carrying out the method and the use thereof
ZA979731B (en) Treatment of asthma.
ZA97986B (en) Treatment of liquors.
ZA975311B (en) Method of enhancing cognition
AU1556497A (en) Agents for the treatment and prevention of aids
CA2347863A1 (en) Treatment of disorders of the outer retina
GR950100091A (en) Method for the treatment of plants.
ZA973843B (en) Treatment of asthma with TNFR-lg.
EP0612506A3 (en) Scalpel to make controlled depth and width incisions.
EP0888780A4 (en) COMPOSITION FOR TREATING CONTACT LENSES AND METHOD FOR USE THEREOF
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
ZA977867B (en) Method of treatment.
ZA975637B (en) Method for the treatment of emesis.
HUP0102995A3 (en) Agents and method for the protective treatment of wood
AU4402497A (en) Methods and means for the treatment of malignancies